JO3352B1 - صيغ دايكلوفيناك وطرق استخدامه - Google Patents

صيغ دايكلوفيناك وطرق استخدامه

Info

Publication number
JO3352B1
JO3352B1 JOP/2006/0177A JOP20060177A JO3352B1 JO 3352 B1 JO3352 B1 JO 3352B1 JO P20060177 A JOP20060177 A JO P20060177A JO 3352 B1 JO3352 B1 JO 3352B1
Authority
JO
Jordan
Prior art keywords
methods
diclofenac
formulations
acute pain
diclofenac formulations
Prior art date
Application number
JOP/2006/0177A
Other languages
English (en)
Inventor
Reiner Alberto
Meyer Andreas
Reiner Giorgio
Original Assignee
Apr Applied Pharma Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3352(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apr Applied Pharma Res Sa filed Critical Apr Applied Pharma Res Sa
Application granted granted Critical
Publication of JO3352B1 publication Critical patent/JO3352B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير طرق وصيغ لعلاج الصداع النصفي ونوبات الألم الحاد الأخرى باستخدام داي كلوفيناك, وصيغ داي كلوفيناك التي توفر كل من التخفيف السريع والمستمر من الألم الحاد, يتم أيضا توفير طرق وصيغ لعلاج أعراض تصاحب في الغالب الصداع النصفي والألم الحاد مثل الرهبة من الضوء والرهبة من الأصوات والغثيان والقيء .
JOP/2006/0177A 2005-06-17 2006-06-11 صيغ دايكلوفيناك وطرق استخدامه JO3352B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69175705P 2005-06-17 2005-06-17
US69202405P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
JO3352B1 true JO3352B1 (ar) 2019-03-13

Family

ID=37396065

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0177A JO3352B1 (ar) 2005-06-17 2006-06-11 صيغ دايكلوفيناك وطرق استخدامه

Country Status (24)

Country Link
US (7) US7759394B2 (ar)
EP (4) EP3103441B1 (ar)
KR (1) KR101352130B1 (ar)
CN (3) CN112755014A (ar)
AR (1) AR057378A1 (ar)
AU (1) AU2006257072B2 (ar)
BR (1) BRPI0612245A2 (ar)
CA (2) CA2632375C (ar)
EC (1) ECSP077989A (ar)
ES (3) ES2912897T3 (ar)
GT (1) GT200600261A (ar)
HK (1) HK1213814A1 (ar)
JO (1) JO3352B1 (ar)
MX (1) MX2007016072A (ar)
NO (1) NO342336B1 (ar)
NZ (1) NZ564002A (ar)
PE (1) PE20070074A1 (ar)
PL (1) PL1890680T3 (ar)
PT (1) PT1890680T (ar)
RU (1) RU2432160C2 (ar)
TR (1) TR201706038T4 (ar)
TW (1) TW200740470A (ar)
WO (1) WO2006133954A2 (ar)
ZA (1) ZA200710858B (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974595B1 (en) * 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US7700125B2 (en) * 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
AU2008253125B2 (en) * 2007-05-24 2013-11-07 Novartis Ag Oral dosage form providing fast absorption of drug
KR101580656B1 (ko) 2009-04-24 2015-12-30 아이슈티카 피티와이 리미티드 디클로페낙의 신규 제형
CN102438594A (zh) 2009-04-24 2012-05-02 伊休蒂卡有限公司 吲哚美辛的新剂型
WO2011036114A1 (en) * 2009-09-25 2011-03-31 Novartis Ag Oral pharmaceutical composition comprising diclofenac
FR2984165B1 (fr) * 2011-12-16 2014-06-27 Pharmeuro Traitement des crises de migraines, notamment d'algies vasculaires de la face
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9855234B2 (en) 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
CN106580886A (zh) * 2016-12-05 2017-04-26 北京万全德众医药生物技术有限公司 一种双氯芬酸钾散剂及其制备方法
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited DICLOFENAC COMPOSITIONS WITH LOW DOSE
EP3893865B1 (en) 2018-12-14 2026-03-25 Apr Applied Pharma Research S.A. Ready to use diclofenac stick packs
WO2021250571A1 (en) 2020-06-10 2021-12-16 Apr Applied Pharma Research, S.A. Bioavailable sugar-based diclofenac formulations
EP3928766A1 (en) 2020-06-26 2021-12-29 Usso Barnas Pharmaceutical composition and use thereof
US20220241230A1 (en) * 2021-02-03 2022-08-04 Patrin Pharma, Inc. Diclofenac sachet composition
CN115317464B (zh) * 2022-09-01 2023-08-08 苏州弘森药业股份有限公司 一种双氯芬酸钾微胶囊及其制备方法
GB2634218A (en) * 2023-09-29 2025-04-09 Approved Pharma Solutions Ltd Powder for oral solution formulations
GB202401873D0 (en) * 2024-02-12 2024-03-27 Hawkins John Lipophilic drug suspensions

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558690A (en) 1965-04-08 1971-01-26 Gelgy Chemical Corp Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
JPS57191962A (en) 1981-05-20 1982-11-25 Hitachi Ltd Fuel cell
IT1209667B (it) 1985-11-12 1989-08-30 Zambon Spa Composizione effeverscente adattivita' analgesica.
CH673395A5 (ar) * 1987-01-30 1990-03-15 Ciba Geigy Ag
US5211957A (en) 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
IT1226549B (it) 1988-07-12 1991-01-24 Resa Farma Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
GB8824392D0 (en) 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
GB8920693D0 (en) 1989-09-13 1989-10-25 Nicholas Kiwi Pty Ltd Non-effervescent ibuprofen compositions
EP0466640B1 (de) 1990-06-28 1995-05-24 Ciba-Geigy Ag Alpha-Carbonylphenylacetonitrilderivate als Stabilisatoren für organische Materialien
EP0466650A2 (en) 1990-07-11 1992-01-15 Warner-Lambert Company Improvements in non-steroidal anti-inflammatory therapy
MX9300110A (es) 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
EP0653935B1 (en) * 1992-08-05 2002-05-08 F.H. FAULDING & CO. LIMITED Pelletised pharmaceutical composition
IT1264696B1 (it) 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
ATE219762T1 (de) 1993-09-07 2002-07-15 Gergely Gerhard Modifizierte kristalle einer festen, essbaren, organischen säure
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
EP0760680A1 (en) 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
DE19538555A1 (de) 1995-10-17 1997-04-24 Beiersdorf Ag Gegen Akne und entzündete Comedonen wirksame Wirkstoffkombinationen
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
US7687542B2 (en) * 1996-05-17 2010-03-30 Kowa Pharmaeuticals America, Inc. Rapidly bioavailable tablet and capsule formulations of diclofenac
US6974595B1 (en) 1996-05-17 2005-12-13 Proethic Pharmaceuticals, Inc. Pharmaceutical compositions based on Diclofenae
US20060013896A1 (en) 1996-05-17 2006-01-19 Giorgio Reiner Methods of treating acute pain using diclofenac
US5854279A (en) 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
DE69905380T2 (de) 1998-09-10 2003-11-27 Nycomed Danmark A/S, Roskilde Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
EP1312355B1 (en) * 2001-11-20 2003-06-11 Apr Applied Pharma Research S.A. Water-soluble non-effervescent pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs
RU2202359C1 (ru) * 2002-05-18 2003-04-20 Агафонов Сергей Александрович Лечебно-профилактическое средство
WO2004098561A2 (en) * 2003-05-08 2004-11-18 Nektar Therapeutics Uk Ltd Particulate materials
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US7700125B2 (en) * 2006-02-07 2010-04-20 Kowa Pharmaceuticals America, Inc. Moisture resistant container systems for rapidly bioavailable dosage forms
US7939561B2 (en) * 2006-02-07 2011-05-10 Apr Applied Pharma Research S.A. Blister packaging for acute pain regimens

Also Published As

Publication number Publication date
ES2717879T3 (es) 2019-06-26
US8097651B2 (en) 2012-01-17
US20070015831A1 (en) 2007-01-18
EP1890680B1 (en) 2017-03-08
US9827197B2 (en) 2017-11-28
CA2632375C (en) 2016-08-16
BRPI0612245A2 (pt) 2010-10-26
US8927604B2 (en) 2015-01-06
AU2006257072B2 (en) 2012-08-16
EP3103441B1 (en) 2022-03-16
EP2705837A1 (en) 2014-03-12
CN112755014A (zh) 2021-05-07
US20100204330A1 (en) 2010-08-12
EP1890680A2 (en) 2008-02-27
US20200323776A1 (en) 2020-10-15
CN104856959A (zh) 2015-08-26
WO2006133954A3 (en) 2007-07-26
AR057378A1 (es) 2007-11-28
ES2912897T3 (es) 2022-05-30
NO20080352L (no) 2008-03-17
RU2008101784A (ru) 2009-07-27
US7759394B2 (en) 2010-07-20
ZA200710858B (en) 2008-12-31
US20150064258A1 (en) 2015-03-05
CN101272768A (zh) 2008-09-24
ECSP077989A (es) 2008-03-26
EP2402003A3 (en) 2012-05-09
EP2705837B1 (en) 2019-02-20
US20130245122A1 (en) 2013-09-19
HK1213814A1 (zh) 2016-07-15
EP2402003B1 (en) 2020-05-06
US20090197961A1 (en) 2009-08-06
KR101352130B1 (ko) 2014-02-06
GT200600261A (es) 2007-02-05
US20170319484A1 (en) 2017-11-09
TR201706038T4 (tr) 2019-02-21
CA2932603C (en) 2017-08-08
PL1890680T3 (pl) 2017-08-31
EP2402003A2 (en) 2012-01-04
ES2641889T3 (es) 2017-11-14
CA2932603A1 (en) 2006-12-21
NO342336B1 (no) 2018-05-07
PT1890680T (pt) 2017-05-05
PE20070074A1 (es) 2007-02-08
RU2432160C2 (ru) 2011-10-27
AU2006257072A1 (en) 2006-12-21
NZ564002A (en) 2011-03-31
KR20080024202A (ko) 2008-03-17
MX2007016072A (es) 2008-03-10
CA2632375A1 (en) 2006-12-21
WO2006133954A2 (en) 2006-12-21
EP3103441A1 (en) 2016-12-14
TW200740470A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
JO3352B1 (ar) صيغ دايكلوفيناك وطرق استخدامه
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
SG155163A1 (en) Pharmacokinetically improved compounds
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY160041A (en) Compositions and methods for treating parasitic infections
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
SG164368A1 (en) Treatment of cancer
ZA200906264B (en) Aminopyrimidines useful as inhibitors of protein kinases
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009003938A (es) Anticuerpos e inmunoconjugados y sus usos.
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors